Q-omics provides the consensus-scored JMJD8 profile across patient tissues and cancer cell-line models. JMJD8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, JMJD8 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, JMJD8 RNA expression shows 18,463 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KICH, and ACC as cancer lineages where JMJD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JMJD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JMJD8 survival associations across molecular data types. JMJD8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JMJD8 RNA expression–survival associations across cancer types. High JMJD8 expression shows unfavorable associations in ACC, LGG, BLCA and CHOL, but favorable associations in HNSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for JMJD8 RNA expression.
This table summarizes JMJD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for JMJD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JMJD8 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LIHC, KIRP and BRCA. The KICH box plot shows higher JMJD8 RNA expression in normal versus tumor tissue (log2 FC = −1.233, t-test p < 0.001).
This table shows molecular features associated with JMJD8 in patient tissues and cancer cell lines. In patient samples, JMJD8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, JMJD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
